Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.

[1]  K. Miyamura,et al.  Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. II. Comparison with the rabbit skin method and practical application for seroepidemiological studies. , 1974, Journal of biological standardization.

[2]  M. Rinaudo,et al.  New method for the quaternization of chitosan , 1986 .

[3]  M. Rinaudo,et al.  13C and 1H n.m.r. spectroscopy of chitosan and N-trimethyl chloride derivatives , 1987 .

[4]  J. Bos,et al.  The skin immune system: progress in cutaneous biology. , 1993, Immunology today.

[5]  Rajesh K. Gupta,et al.  Adjuvants--a balance between toxicity and adjuvanticity. , 1993, Vaccine.

[6]  E. Raz,et al.  Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Brook,et al.  Novel polymer‐grafted starch microparticles for mucosal delivery of vaccines , 1996, Immunology.

[8]  J. Brussee,et al.  Preparation and NMR characterization of highly substitutedN-trimethyl chitosan chloride , 1998 .

[9]  G. Matyas,et al.  Skin immunization made possible by cholera toxin , 1998, Nature.

[10]  Lisbeth Ilium,et al.  Chitosan and Its Use as a Pharmaceutical Excipient , 1998, Pharmaceutical Research.

[11]  K. Vårum,et al.  Quantitative determination of chitosans by ninhydrin , 1999 .

[12]  V E Schijns,et al.  Immunological concepts of vaccine adjuvant activity. , 2000, Current opinion in immunology.

[13]  H. Merkle,et al.  Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[14]  J. Hamman,et al.  Effect of the Type of Base and Number of Reaction Steps on the Degree of Quaternization and Molecular Weight of N-Trimethyl Chitosan Chloride , 2001, Drug development and industrial pharmacy.

[15]  Yuetsu Tanaka,et al.  Microbial Compounds Selectively Induce Th1 Cell-Promoting or Th2 Cell-Promoting Dendritic Cells In Vitro with Diverse Th Cell-Polarizing Signals1 , 2002, The Journal of Immunology.

[16]  W. Hennink,et al.  Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines. , 2003, Vaccine.

[17]  P. Tyler,et al.  Liposomal delivery of antigen to human dendritic cells. , 2003, Vaccine.

[18]  T. Kupper,et al.  Immune surveillance in the skin: mechanisms and clinical consequences , 2004, Nature Reviews Immunology.

[19]  Mark R Prausnitz,et al.  Microneedles for transdermal drug delivery. , 2004, Advanced drug delivery reviews.

[20]  H E Junginger,et al.  Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[21]  Dexiang Chen,et al.  Epidermal powder immunization against influenza. , 2004, Vaccine.

[22]  Jie Li,et al.  Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1 , 2004, The Journal of Immunology.

[23]  R. Rappuoli,et al.  Novel Approaches to Vaccine Delivery , 2004, Pharmaceutical Research.

[24]  Gerrit Borchard,et al.  Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. , 2004, Vaccine.

[25]  S. Vandermerwe.  Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs , 2004 .

[26]  David J Brayden,et al.  Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. , 2005, Drug discovery today.

[27]  S. Correa,et al.  Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration , 2005, Journal of leukocyte biology.

[28]  C. Wischke,et al.  Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[29]  M. Cormier,et al.  Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. , 2006, Vaccine.

[30]  H. Junginger,et al.  Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[31]  S. Fleischer,et al.  Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots , 1970, Lipids.

[32]  J. Stockman.  Dose Sparing With Intradermal Injection of Influenza Vaccine , 2006 .

[33]  Ulrike Blume-Peytavi,et al.  40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. , 2006, The Journal of investigative dermatology.

[34]  Vasso Apostolopoulos,et al.  Pathogen recognition and development of particulate vaccines: does size matter? , 2006, Methods.

[35]  H. Junginger,et al.  N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. , 2007, Vaccine.

[36]  H. Junginger,et al.  Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[37]  Gaëlle Vandermeulen,et al.  Optimisation of intradermal DNA electrotransfer for immunisation. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[38]  J. Schlom,et al.  Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. , 2007, Vaccine.

[39]  M. Akashi,et al.  Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. , 2007, Biomaterials.

[40]  Kwok-Hung Chan,et al.  Immunogenicity and Safety of Intradermal Influenza Immunization at a Reduced Dose in Healthy Children , 2007, Pediatrics.

[41]  David Leong,et al.  Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. , 2007, Molecular pharmaceutics.

[42]  W. Hennink,et al.  Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. , 2007, Vaccine.

[43]  Tejraj M Aminabhavi,et al.  Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[44]  S Senel,et al.  Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. , 2008, International journal of pharmaceutics.

[45]  Wen-Tao He,et al.  Transdermal permeation enhancement of N-trimethyl chitosan for testosterone. , 2008, International journal of pharmaceutics.

[46]  C. Katlama,et al.  Transcutaneous Anti-Influenza Vaccination Promotes Both CD4 and CD8 T Cell Immune Responses in Humans1 , 2008, The Journal of Immunology.

[47]  B. Everts,et al.  Combined TLR2 and TLR4 ligation in the context of bacterial or helminth extracts in human monocyte derived dendritic cells: molecular correlates for Th1/Th2 polarization , 2009, BMC Immunology.

[48]  W. Hennink,et al.  Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated chitosan. , 2008, Biomaterials.

[49]  B. Guy,et al.  Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice , 2008, Expert review of vaccines.

[50]  W. Jiskoot,et al.  Physicochemical and Immunological Characterization of N,N,N-Trimethyl Chitosan-Coated Whole Inactivated Influenza Virus Vaccine for Intranasal Administration , 2009, Pharmaceutical Research.

[51]  P. van Damme,et al.  Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. , 2009, Vaccine.

[52]  W. Jiskoot,et al.  Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[53]  W. Jiskoot,et al.  Immune Modulation by Adjuvants Combined with Diphtheria Toxoid Administered Topically in BALB/c Mice After Microneedle Array Pretreatment , 2009, Pharmaceutical Research.

[54]  J. Bouwstra,et al.  Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. , 2009, Journal of controlled release : official journal of the Controlled Release Society.